MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
Amicus Therapeutics Cash and Cash Equivalents 2011-2026 | FOLD
Annual Cash and Cash Equivalents Amicus Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 214 M | 214 M | 247 M | 149 M | 245 M | 163 M | 143 M | 79.7 M | 49.1 M | 187 M | 69.5 M | 24.1 M | 43.6 M | 34 M | 25.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 247 M | 24.1 M | 126 M |
Quarterly Cash and Cash Equivalents Amicus Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 191 M | 159 M | 182 M | 214 M | 234 M | 209 M | 210 M | 247 M | 263 M | 211 M | 161 M | 149 M | 278 M | 236 M | 233 M | 245 M | 386 M | 177 M | 185 M | 163 M | 163 M | 163 M | 163 M | 143 M | 143 M | 143 M | 143 M | 79.7 M | 79.7 M | 79.7 M | 79.7 M | 49.1 M | 49.1 M | 49.1 M | 49.1 M | 187 M | 187 M | 187 M | 187 M | 69.5 M | 69.5 M | 69.5 M | 69.5 M | 24.1 M | 24.1 M | 24.1 M | 24.1 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 34 M | 34 M | 34 M | 34 M | 25.7 M | 25.7 M | 25.7 M | 25.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 386 M | 24.1 M | 126 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
1.91 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
261 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B |  Britain |
 |
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
54 M | - | 0.74 % | $ 768 M |  Israel |
 |
Galera Therapeutics
GRTX
|
6.38 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
168 M | $ 3.14 | 0.16 % | $ 653 M | USA |
 |
Eton Pharmaceuticals
ETON
|
25.9 M | $ 35.13 | 1.97 % | $ 945 M | USA |
|
Forte Biosciences
FBRX
|
77 M | $ 21.7 | 6.84 % | $ 281 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
12.4 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Grifols, S.A.
GRFS
|
980 M | $ 8.14 | -0.67 % | $ 5.53 B |  Spain |
 |
Generation Bio Co.
GBIO
|
76.3 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
21.2 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
7.68 B | $ 91.21 | 0.94 % | $ 22 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
104 M | $ 1.66 | 2.47 % | $ 442 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
28.6 M | $ 0.87 | 2.78 % | $ 145 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.5 M | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
90.6 M | $ 2.61 | -3.7 % | $ 244 M | Israel |
 |
Incyte Corporation
INCY
|
3.1 B | $ 97.69 | 0.63 % | $ 19.1 B | USA |
 |
Anika Therapeutics
ANIK
|
57.5 M | $ 15.09 | -0.33 % | $ 216 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M | Canada |
 |
Ionis Pharmaceuticals
IONS
|
372 M | $ 75.94 | 1.17 % | $ 12.2 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.53 M | $ 3.4 | 2.41 % | $ 5.6 M | Israel |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
88.9 M | $ 1.6 | 5.61 % | $ 187 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
17.8 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 20.88 | 2.0 % | $ 2.66 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |